Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

Timothy A. Bates, Hans C. Leier, Zoe L. Lyski, Savannah K. McBride, Felicity J. Coulter, Jules B. Weinstein, James R. Goodman, Zhengchun Lu, Sarah A. R. Siegel, Peter Sullivan, Matt Strnad, Amanda E. Brunton, David X. Lee, Andrew C. Adey, Benjamin N. Bimber, Brian J. O’Roak, Marcel E. Curlin (), William B. Messer () and Fikadu G. Tafesse ()
Additional contact information
Timothy A. Bates: Oregon Health & Science University (OHSU)
Hans C. Leier: Oregon Health & Science University (OHSU)
Zoe L. Lyski: Oregon Health & Science University (OHSU)
Savannah K. McBride: Oregon Health & Science University (OHSU)
Felicity J. Coulter: Oregon Health & Science University (OHSU)
Jules B. Weinstein: Oregon Health & Science University (OHSU)
James R. Goodman: Medical Scientist Training Program, OHSU
Zhengchun Lu: Oregon Health & Science University (OHSU)
Sarah A. R. Siegel: OHSU-PSU School of Public Health, Program in Epidemiology
Peter Sullivan: OHSU-PSU School of Public Health, Program in Epidemiology
Matt Strnad: OHSU-PSU School of Public Health, Program in Epidemiology
Amanda E. Brunton: OHSU-PSU School of Public Health, Program in Epidemiology
David X. Lee: Oregon Health & Science University (OHSU)
Andrew C. Adey: OHSU
Benjamin N. Bimber: Vaccine and Gene Therapy Institute, OHSU
Brian J. O’Roak: OHSU
Marcel E. Curlin: OHSU
William B. Messer: Oregon Health & Science University (OHSU)
Fikadu G. Tafesse: Oregon Health & Science University (OHSU)

Nature Communications, 2021, vol. 12, issue 1, 1-7

Abstract: Abstract SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the rollout of effective vaccines. Therefore, it is essential to understand the levels of protection that these vaccines provide in the face of emerging variants. Here, we report two demographically balanced cohorts of BNT162b2 vaccine recipients and COVID-19 patients, from which we evaluate neutralizing antibody titers against SARS-CoV-2 as well as the B.1.1.7 (alpha) and B.1.351 (beta) variants. We show that both B.1.1.7 and B.1.351 are less well neutralized by serum from vaccinated individuals, and that B.1.351, but not B.1.1.7, is less well neutralized by convalescent serum. We also find that the levels of variant-specific anti-spike antibodies are proportional to neutralizing activities. Together, our results demonstrate the escape of the emerging SARS-CoV-2 variants from neutralization by serum antibodies, which may lead to reduced protection from re-infection or increased risk of vaccine breakthrough.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-25479-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25479-6

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-25479-6

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().